Identification and analysis of immune cell-related genes in cutaneous squamous cell carcinoma and drug network prediction

被引：0

作者：

Wang, Baoyun ^{[1
]}

Zheng, Deyi ^{[1
]}

Du, Jiao ^{[1
]}

Yang, Yang ^{[1
]}

机构：

[1] Guizhou Prov Peoples Hosp, Dept Burn & Plast Surg, Guiyang 550002, Guizhou, Peoples R China

来源：

ARCHIVES OF DERMATOLOGICAL RESEARCH | 2024年 / 317卷 / 01期

关键词：

Cutaneous squamous cell carcinoma; Immune cells; Biomarkers; Immunotherapy; RISK-FACTORS; EXPRESSION; CANCER;

D O I：

10.1007/s00403-024-03587-9

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Cutaneous squamous cell carcinoma (CSCC) is a malignant skin tumor characterized by the abnormal proliferation of keratinocytes. Immune cells have a very important role in the development of CSCC. Hence, it was vital to screen the immune cell-related biomarkers for the treatment of CSCC. Gene set variation analysis (GSVA) and immune infiltration analysis were utilised to obtain key immune cells. Weighted gene co-expression network analysis (WGCNA) was conducted to screen key module genes related to immune cell. At the same time, differential analysis was performed to find the differentially expressed genes (DEGs) between CSCC and normal samples. The candidate genes related to immune cell in CSCC patients were certificated by Venn diagram. Protein-protein interaction (PPI) network and receiver operating characteristic (ROC) curves were selected for identifying biomarkers of CSCC. We further performed immunotherapy analysis between two expression subgroups based on single gene. Following by this, the DRUGBANK database was applied to explore the interactions between biomarkers and available therapeutic agents. Finally, the expression of biomarkers was verified through real-time quantitative polymerase chain reaction (RT-qPCR). A total of 4 key immune cells (M0 macrophages, resting dendritic cells, resting mast cells, and activated mast cells) were identified. Furthermore, we obtained 982 key module genes related to immune cell. Meanwhile, 646 differentially expressed genes (DEGs) were identified. Hence, 63 candidate genes related to immune cell were selected by Venn diagram. Then, we identified six biomarkers (SLC27A2, ACOX2, PECR, CRAT, FADS1 and ELOVL5) were screened. High expression group of biomarkers showed relatively high expression of immune checkpoints. Additionally, we found 10 drugs with potential therapeutic value targeting biomarkers. Eventually, the lower expression of biomarkers in tumor group was observed, which was consistent with the result from public databases. Overall, we obtained six immune cell-related biomarkers (SLC27A2, ACOX2, PECR, CRAT, FADS1 and ELOVL5) associated with CSCC, which laid a theoretical foundation for the treatment of CSCC.

引用

页数：12

共 39 条

[1]

Bander T.S., Nehal K.S., ) Cutaneous Squamous Cell Carcinoma: Updates in Staging and Management [J, ]. Dermatol Clin, 37, 3, pp. 241-251, (2019)

[2]

Soura E., Gagari E., Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? [J], Curr Opin Oncol, 31, 5, pp. 461-468, (2019)

[3]

Rosenthal A., Stoddard M., Skin cancer prevention: a review of current topical options complementary to sunscreens [J], J Eur Acad Dermatol Venereol, 33, 7, pp. 1261-1267, (2019)

[4]

Tam S., Gross N., Cutaneous squamous cell carcinoma in immunosuppressed patients [J], Curr Oncol Rep, 21, 9, (2019)

[5]

Gay J., Johnson N., Utility of the human papillomavirus vaccination in management of HPV-associated cutaneous lesions [J], Skin Therapy Lett, 26, 2, pp. 6-8, (2021)

[6]

Nardone V., Gagliardi N., Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: a retrospective analysis [J], J Am Acad Dermatol, (2024)

[7]

Komatsubara KM J., Carvajal R., Et al., Advances in the treatment of Advanced Extracutaneous Melanomas and Nonmelanoma skin cancers [J], Am Soc Clin Oncol Educ Book, 37, pp. 641-650, (2017)

[8]

Brantsch KD Meisner C., SCHoNFISCH B., Et al., Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study [J], Lancet Oncol, 9, 8, pp. 713-720, (2008)

[9]

Tanese K., Nakamura Y., Hirai I., Et al., Updates on the systemic treatment of Advanced non-melanoma skin Cancer [J], Front Med (Lausanne), 6, (2019)

[10]

Wayteck L., Breckpot K., Demeester J., Et al., A personalized view on cancer immunotherapy [J], Cancer Lett, 352, 1, pp. 113-125, (2014)

← 1 2 3 4 →